Sort
3,198 grants matching “mrna vaccine”
Regulation of B Cell Development by Neuropeptides
$275,120University Of Kentucky · R01 · FY2005 · NS
Regulation of B Cell Development by Neuropeptides
$275,120University Of Kentucky · R01 · FY2004 · NS
STTR Phase I: Development of Thermostable Formulations of mRNA Vaccines and Therapeutics
$274,991Harrison R Wooten · Duravax Inc · · FY2024 · TIP
SBIR Phase I: Development of a Novel Platform for Cost-Efficient mRNA Production in Yeast
$274,980Hari Bhaskaran · Cisterna Biologics, Inc. · · FY2024 · TIP
SBIR Phase I: Proof-of-concept of a customizable, next-generation RNA delivery particle
$274,947Patrick McTamney · Lattice Therapeutics Inc · · FY2024 · TIP
STTR Phase I: GEX: an mRNA-based tolerogenic vaccine for viral-based gene therapies
$274,763Alex R Hill · Genexgen Inc · · FY2024 · TIP
Defining the Protective vs. Susceptible Immune Proteome of S. aureus Osteomyelitis
$274,504Edward M Schwarz · University Of Rochester · P50 · FY2022 · AR
Rotavirus interaction with gut intraepithelial lymphocytes
$272,125Siyuan Ding · Washington University · R21 · FY2023 · AI
Stomach musosal and Adaptive immunity to Helicobacter pylori
$271,491William G. Coleman · National Institute Of Diabetes And Digestive And Kidney Diseases · Z01 · FY2008 · DK
Amazonian Center of Excellence in Malaria Research
$271,491Ricardo Gazzinelli · Yale University · U19 · FY2023 · AI
CYTOADHERENCE IN MATERNAL MALARIA
$271,442Channe D Gowda · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2008 · AI
CYTOADHERENCE IN MATERNAL MALARIA
$271,408Channe D Gowda · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2009 · AI
Project #3:Active Vaccination and Immunotherapy Against Coccidioidomycosis
$271,399Chiung-Yu Hung · University Of Texas San Antonio · U19 · FY2025 · AI
RNA Processing in Non-Segmented Minus-Strand RNA Viruses
$271,171Sean P. J. Whelan · Harvard Medical School · R01 · FY2015 · AI
CORE--TISSUE SPECIFICITY
$270,039University Of Virginia Charlottesville · U54 · FY2000 · HD
The Neuroprotective Effect of HSP72 Induction in Experimental Glaucoma
$269,500Natik Piri · University Of California Los Angeles · R01 · FY2009 · EY
Development of ERBB2 Based Breast Cancer Vaccines
$269,170Wei-Zen Wei · Wayne State University · R01 · FY2007 · CA
Aalysis of immune receptor diversity and oligoclonality in responses to vaccinati
$268,208Andrew Z. Fire · Stanford University · U19 · FY2011 · AI
Natural History of CIN2 in Adolescents
$268,000Anna-Barbara None Moscicki · University Of California, San Francisco · R01 · FY2007 · CA
Defining the Protective vs. Susceptible Immune Proteome of S. aureus Osteomyelitis
$267,775Edward M Schwarz · University Of Rochester · P50 · FY2024 · AR
Project 3: Dr. Li
$267,008Jianrong Li · Research Inst Nationwide Children'S Hosp · P01 · FY2017 · AI
Potent Signal 1 as a noncanonical Signal 3: antigen location, and peptide:MHCII complex density and half-life as drivers of CD4+ T cell differentiation
$267,000Laurence Crane Eisenlohr · Children'S Hosp Of Philadelphia · R21 · FY2025 · AI
Interference by Defective influenza Viruses
$266,875University Of California Los Angeles · R01 · FY2005 · AI
Interference by Defective influenza Viruses
$266,875University Of California Los Angeles · R01 · FY2004 · AI
The Neuroprotective Effect of HSP72 Induction in Experimental Glaucoma
$266,805Natik Piri · University Of California Los Angeles · R01 · FY2010 · EY